RxDoctor Payments Data

James Wilson, MD

Cardiovascular Disease · Houston, TXNPI 1194827337

Payments from drug & device makers

$3,263in general payments, 2019–2025

Across 53 payments — averaging $61.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$484
  • Cathworks, Inc.$231
  • Alphatec Spine, Inc$141
  • Johnson & Johnson$131
  • Esperion Therapeutics, Inc.$125
  • plus $801 from 13 others

What the payments were for

  • Travel & lodging$38212%
  • Food & beverage$2,82287%
  • Education$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,263 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$308,134
Medicare patients
407
Services billed
2,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$183,900
Repatha SureclickEvolocumab87$76,355
XareltoRivaroxaban65$71,253
JardianceEmpagliflozin18$30,328
EntrestoSacubitril/Valsartan15$26,659
FarxigaDapagliflozin Propanediol25$24,507
Praluent PenAlirocumab18$23,073
KerendiaFinerenone18$22,215
Repatha SyringeEvolocumab18$15,463
MounjaroTirzepatide11$14,946
OzempicSemaglutide12$14,230
Ezetimibe252$8,559
Metoprolol Succinate224$3,252
Atorvastatin Calcium290$3,197
Nifedipine ErNifedipine49$2,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$183,900134 claims
Johnson & JohnsonXarelto$131$71,25365 claims
Boehringer IngelheimJardiance$81$30,32818 claims
NovartisEntresto$95$26,65915 claims
AstraZenecaFarxiga$94$24,50725 claims
BayerKerendia$95$22,21518 claims
Novo NordiskOzempic$47$14,23012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →